Quality control in the regulation of pharmaceuticals

PharmacoEconomics

Volumn 23, Issue 5, 2005, Pages 421-422

  Maynard, Alan ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; ECONOMIC ASPECT; EDITORIAL; EUROPE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; MEDICAL PROFESSION; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; QUALITY CONTROL;

DRUG INDUSTRY; GREAT BRITAIN; LEGISLATION, DRUG; QUALITY CONTROL; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE;

EID: 22244449670     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523050-00001     Document Type: Editorial

References (6)

1. Maynard A, Bloor K. Regulating the pharmaceutical industry. BMJ 1997; 315: 200-1
2. Steinbrook R. Registration of clinical trials: voluntary or mandatory? N Engl J Med 2004; 351 (18): 1820-2
3. Abbasi K. Editor's choice. BMJ 2005, 330
4. Williams M. An inquiry by the UK House of Commons Select Committee into the influence of the pharmaceutical industry [online]. Available frm URL: http://www.meactionuk.org.uk/HoC_Select_Ctte_Inquiry_into_Pharma.htm [Accessed 2005 Apr 28]
5. Miners AH, Garau M, Fidan D, et al. Comparing estimates of cost effectiveness submitted to the National Institute of Clinical Excellence (NICE) by different organisations: a retrospective study. BMJ 2005; 330: 65-8
6. Maynard A, Bloor K, Freemantle N. Challenges for the National Institute of Clinical Excellence. BMJ 2004; 329: 327-9